please Slide Yes Matt. Thanks, Yes. turn – so to yes, XX.
And lens study Roivant bit take as of, what to of by extent going end investors, to to our some To have pivotal I this get through notice giants sleeping I true, about So year. lupus I for the one mostly the year. that Matt think, that talk while this later is for data said, one the is consider brepocitinib within of do a think the we the want of portfolio. the it’s little being I opportunity catalyst a
what I think of build the we’re with lupus small to story a part trying just is brepocitinib.
that from on is want And to punch I so don’t the here line, of story brepocitinib. perspective, sweat today, go fresh my through
of range highly, spectacular JAKX So a efficacy auto and dual in already highly of shown a both active is simply, brepocitinib broad inhibitor put TYKX that immune has unique, diseases.
studies alopecia, as time now to positive II you positive being said, pertiva this on Crohn’s consecutive run And expense. disease, is Matt a hidradenitis is by that already brepocitinib adds first covering that time toric ulcerative arthritis, study psoriasis, the II for the reporting see nacho string the here as for sixth which study and [indiscernible] in we’re colitis, the reported, So Pfizer here of disease. and to Phase slide, Phase
loop That we’ll TYKX later, given And we as oral inhibition have global which a X therapy studies. think of but has registrational is slide serve that either endpoint, detail designed been a study provide is is study the of predictive material future primary greater leading in that studies. the it the the should and through become is inhibition we X with that registrational this the endpoint And and importantly, one the to most historically than the potential greater XX-week efficacy of of of to JAKX dual go large alone. on really a XX-week rest
which dermatomyositis, basis seems of is a asset in serve coming study Our now data, ongoing off. it extent III single to will filing as little shortly Phase up, far an the NDA the that
as and catalyst we XXXX, come as of just year round for the a program. in And that’s I half are sitting first into think the this beginning near-term it focus the out will ever.
that has we potential XXXX. think which a high need dual really the So at have revenue creates unique brepocitinib, and for least and protection can And finally, approach a blockbuster we that, then series a each to we’ll with we high IP of long that coming of slides. runway pipeline and specialty product here show unmet and of own in efficacy mechanism the where demonstrated indications, brepocitinib rheumatology
turn Please Slide to XX.
JAKX, family JAK autoimmune has JAKX, powerful So disease. be wide spectrum family many of the the as years a know, treating consists JAKX past to IsoPol several and over JAK of inhibition mechanism TYKX. enormously an you for proven X The of
moving biology to field While stubernly accumulated on and you the see and top, underlying the as remains [indiscernible] across approval in complex has a the rheumatology irreducible. starting often
autoimmune here Soon drive key JAK been cytokines a along for key the simplified those have number to of with detailing shown disease schematic isoforms signaling a responsible pathway. of that is pathobiology mediating
applicability inhibitors nonselective first JAKX more explored. unsurprisingly, inhibitors While trended be and in the the the having early JAK recently broadest towards were with specific to therefore, relatively more field has
selective and band JAKX not most cytokines impacted. blue two inhibitors dark interferon that are You middle cytokines as gamma, to such the here as signaling press are can see able a autoimmunity the the suppressed important are that selective JAKX RINVOQ linked and or IL-X across in of to inhibition. inhibitors Notably, directly
of of of IL-XX selective the out TYKX many as a cover and The auto TYKX pathogenic downstream on you the set can inhibitors, Key They light and these and the set Now the reduction, in right. drives in among cells ThXX the particular indications. which latter IL-XX different activation of blue XX. coming key scene are immune a such of driver differentiation of diseases. now which the a cytokines, see
JAKX benefit commercial approaching of a both success meaningful from to and of of $X track also Sotyktu record multibillion-dollar these of range many product. across approaches revenue accumulating their are billion spite also have a a already their quarter, RINVOQ in per limitations. medicines and projected clinical Now is TYKX disease. and net both be successes, But
Sotyktu, and while II RINVOQ lackluster in outright crowns, for produced and both both failed Phase ulcerative NHI. instance, data colitis in lupus has
at least this to bio. see We part the in connected underlying
clinically true date for meaningful inflammatory at see heterogeneous While to which loan, inflammatory highly limited. require see high orthogonal for pathways may a many to efficacy JAKX some across maximum treatable patient have and selective effect even maybe be meaningful effect or burden The diseases, intervention or well is inhibition disease and latter may all. others multiple by [indiscernible] involve multiple TYKX especially to
drove the slowly with JAK field So its state Roivant, getting be that’s specific maximizing at inhibitors. TYKX of be in highly JAKX pots current what might that efficacy or table high not left the inhibition power that our certain on indications in the may original
the search probably deepest Pfizer, ended prove in the molecule hypothesis, company the with partnering for out So the longest we industry. to right with and JAKs in unsurprisingly this history up with experience our
a we efficacy. do. what a molecule Simultaneous novel deliver we creates safe differentiated opportunities brepocitinib and well-characterized with to can looking highly JAKX, TYKX with of perfectly X which both In for found suited brepocitinib, accomplish we distinct inhibition and uniquely active, are to mechanism
Type hit and the largely diseases dual right signaling the slide. by heterodimer X the bottom page, For and that second shown schematic say alpha beta, on interferon both interferon is sides a of from on to in the driven in
broad be and greater for B-cell And to for way and hand, JAKX pathways the greater with JAKX not treatable on allow in to X with possible potentially that include, or and actually access instance, brepocitinib cytokine IL-X second, hitting suppression diseases inhibition. TYKX involvement May the and on alone. TYKX a IL-XX efficacy thus to would as either IL-XX/XX be or other may that compared
and in the coverage. that’s bottom the JAKX in cytokine deliver line. core best-in-class So requiring hypothesis diver in the mediated TYKX will indications by Brepocitinib stated diseases efficacy broad
Please turn Slide XX. to
So assays, at we concretely excitement cytokine what we saw our looked So exactly what series brepocitinib? to start, to when standard hope drove inhibition a of see. we of
you The signaling, be by would of what have here a That’s run shown So studies experimentally results autoimmune looks to are inhibition and inhibition battle leading JAKX expected pure and at where the an and the effect. across interferon key type multiple inhibition X. inhibitor. by internally leading driver X X at NICE one exactly inhibitor NICE left diseases TYKX the both with see JAKX
slide. Sotyktu. even X then able importantly, or is This well And prior have data experimental been RINVOQ is what that Pfizer’s the predicted type as brepocitinib suppress or exactly to interferon as potentially showed in than signaling would either better
from a inhibition achieving signal. double benefiting hit are greater X type or of the brand We thus and
other show critical we X cytokine drivers. right, the On
we the by see gamma, right, not which JAKX mediated interferon X on So interferon, TYKX. Type by top but is
is So you’d what the pattern inhibition of again, expect.
and RINVOQ inhibitor X brepocitinib, that selective higher inhibition interferon see which gamma Sotyktu. a inhibit compared of have both You relatively specific of to degree TYKX a JAK
and for assay performance of drugs And isoform JAKX then the not opposite are a on you which cytokine on IL-XX right, bottom the the both XX, inhibition from single see median. and TYKX
expect we unique the a see schematic TYKX the outperforming what that’s mediated Here see based slide. And showed of the brepocitinib that is exactly this the asset. on by inhibitor, to more nice RINVOQ the TYKX cytokine a action we prior very, is again, in very modest. much you in Sotyktu, while TYKX inhibition Again, we’d
here, the let’s The bottom. conclusions at
either single see On both reach agent leading profile the in alone TYKX the the suppression left, And the should the or you X brepocitinib of type right, suppression sufitulate hit. cytokine and the can and interference targeting dual of can as brepocitinib JAKX. achieve greater JAKX for by by a leading possible virtue molecule on TYKX
a Please Phase translated data date. cytokine That of experimental turn vision readouts into to II Slide well string has data XX. to
meaningful you in see, efficacy pattern has oral As indication of extremely single demonstrated an clinical every can brepocitinib tested. consistent
Pfizer. and small alopecia, or as psoriasis I’ll which other drug than ulcerative Efficacy were colitis, all caricarthritis, cover The results with good better data, that a and statistically consistent molecule taking HS to HS later, was for readout any significant recent inhibitor. from the occurred subsequent relatively over our
large today excited of Phase induction results We’re a II also study the Crohn to reporting run be Pfizer. by global
So I’ll in slide. the details provide following some additional
the package on another have clinical have benefit safety know we well. we Finally, as brepocitinib. what for We in major
JAKX know lead show. safety efficacy we to and advantages that stacking the that to apparently So a hope undercuts inhibition not profile we does both TYKX inhibition that
database And in safety now extensive II I to is Phase of Our clinical Phase what approved studies with across profile a and seen X,XXX line for patients JAK XX different exposed up consists family safety well-characterized over inhibitors. weeks. XX we’ve
Slide turn Please XX. to
the top CDXX pleased results II study. primary Phase with is So global The This patient induction of portion a who XXX XX, today remission disease. endpoint than of SES a study significant. the highly to of we’re less the Crohn’s from was II endpoint report the initially rate key XXX line week were both and achieved Phase clinical a the repository defined was endpoints patients as CDAI proportion secondary at
SES-CDXX slight the it think study been imbalance the We have drug understated there the a made which the baseline arm. up in achieve arms in for as severity actually ended might between that endpoint on that to true the being efficacy harder
with sure takes only is on into imbalance strong point an that any point of account that is on delivered or the secondary patients since not yet baseline and CDAI is have here than impact end the has it I’m investor’s calculated start trial to efficacy. That this a endpoint that, would that line wasn’t The radar greater a to equal XXX. really way
delta remission, a the study oral as used the late-stage in seen on or In fact, important co-primary is for highest is, drug prescribers endpoint which XX.X% is any to particularly in fact, that placebo-adjusted in from clinical studies and date. registrational biologic
to turn Please Slide XX.
So in an we enviable ourselves position. find
where variety that have highly but market in translation we and indications. brepocitinib, with efficacious of strong clinical molecule lots There do has large things vision a could biologic that So our we are step maximum a of to and for patients brepocitinib a we with indications investors. deliver patients, improvement was start those return impact on generating for in really for maximum could from the focus our outcomes function
To that end, indications disease where of shine. ourselves the ask brepocitinib really we unique are what the properties
For us, left a that side considerations of down on to came few the laid simple slide. out the
and clockwise, light So and efficacy. inhibition required first moving blue is for where in the maximal both TYKX the of JAKX
biologic rationale TYKX validation. corresponding JAKX for clinical look we Here and for inhibition dual
Second, And extremely high which provide have mortality, creating for few and the dark need benefit. novel third, meaningful available including therapies. treatments, pink that flu, in morbidity a indications in efficacy approved no has indication because therapies a oral
to And an need on markets. [indiscernible]. we into experiment, leading course, remember, But think Put of go minimizing regulatory next just a opportunity confident beginning. more that become and development that’s the run could detail finally, of there’s we uncoded two an in and together, for efficient slides a The to we option series treatment that the large will and those risk. be brepocitinib
become indication plus cystic and a products. where small XX. $X to with molecules billion large like is Please a indications profile to orphan similar fibrosis turn very PAH Dermatomyositis have Slide oral
medical XX in time. proven and the Over understood led to awareness over the disease become estimates higher much incidents has has diagnosis years, and and dermatomyositis better an past increasing community, characterized
claims that XXXX own XX,XXX analysis estimate well. with pavilion and as adult recently data XXXX estimates at the We’ve U.S. file patients, consistent done from our with sits to
we time. patient looking and patients awareness in of large an of is we’re population indication. number that the orphan And ultrarare to the category. at the increase disease already not to So grow a This over is clearly as diagnosis continues expect
cover skin many living with of autoimmune mortality years. in is patients, proximal of addition up muscle wheelchairs. a high impact also up The on Many percentages presents shown rash dermatomyositis severely is the pain right, strikingly and patients activity. estimates walkers body to disease X acting large to to this XX% burden. characteristic majority end of high of an disease some lead significant can The vast daily at the suffer For from patients weakness, or disfigurement. meeting There which
meaningful disease. suffer Finally, patients lung proportion a intertial from of
a disease industry-sponsored in there systems approved is development. highly organ this covers inflammatory been past therapies large sum, mortality, which NCEs and that, into are late-stage XX no no oral a In On there multiple market. and will years, commercial of the high evolve in top have
approved convenience present ISTs But and recently for in have current IVIG, and Steroids, side not modern drug including safety in of again, effects, indication high gaining and for days used is X instance, infusions is many the thrombotic addition multi-hour month to approval. or more with years, the single a and requires IVIGs been for treatment quite formal burdens with there rate the benefit. latter options for every limited events. high associated a
of the in modern for particularly CDM really and we market opportunity rapidly one an the to enter as of one in all disease autoimmune therapy, Oral major unmet a and So targeted needs a other therapies small than in development brepocitinib. few become and very oral late-stage no number Phase while blockbuster products. a there of III, drugs proof-of-concept studies, companies in are And exploring are
overall product we across X we material ahead next driver our this become think in sales years. looking commercial has the brepo to a this pipeline a think of launch So market about potential just in the Roivant over years, the to as X-plus for
Slide Please turn XX. to
report. driven disease This type the aligns extensive interferon DM. pathobiology by part to is as where clinical modern see investigator-initiated corticosterone, indication result, very inhibition for the which various to approved medicines add is validation case often signal. meaningful We an of different a DM, therapies the physicians no large in for JAKX the to also and X this of success case With body as with for X There experiment high. Bret in studies on type with in is an
approved of if was for just REPO both an can that that Given of potency even efficacy brepocitinib industry-sponsored well the benefit addition for TYKX but are inhibition clear to or other level reason the also type matched inhibitors enhance set up success there’s this add of to DM, provide, to further interferon commercial will no X that development us believe JAKX suppression.
which in of also turn through pathobiology. to well involved As and Please IL-XX Slide XX, suppression are XX. as
Given in III high step the we high a unmet that need our success, study. bold moving of into the Phase took single competence directly a registrational program poor involves
and in this filing that also market The support line study, NDA potential oral is NDA of XXXX. by Phase later data be us underway, expectation time successful, single well an first enrollment to years if XXXX positioned development. and This a would tracking biologics to Our few a the ahead stage filing and potentially III has complete for DM. several in to brepocitinib in already is clearly likely with study
move to be inflection until idiosyncratic means major a DM in III, it catalyst consequence Roivant that One of for that billion-plus a won’t But next could our decision coming immediately our a $X product potential directly point fall. XXXX. is to line with catalyst into be business. Phase
a an launch to base, And in than prescriber volume would this would significantly given steeper expect for product ramp be we the indication VTAMA. like be orphan revenue with a specialized
is beyond, right think you as that value may we now years major over additional investors X a think this and be So first P&L about next underappreciated. modeling the
major talk But where of lupus. that’s first, pivotal bit. a orphan talk see I we a where the ongoing later more coming study this a opportunity similar many where indication have an to catalyst indications Please have want we we turn not in those do and the few year, first to other up a brepocitinib XX. to Slide about is of for DM
in a attention of is thousands lupus So one from patients amount well lupus disease. of an with suffer that’s is recent that of U.S., serious and increasing in gotten does in Hundreds defeating years. everyone industry many and the that disease from
SRI-X for Enlist efficacy have Only how – approved field of desperate billion occupancy, at between be launched didn’t X% $X.X the and placebo-adjusted XX% years, other and placebo-adjusted two data. sign showed the SRI in is to XX $X as doing very mixed which fiscal One despite therapies is product to the show is study revenue X. billion-plus III modest a greater both in past while a XX% projected injectables U.S. approved about consistence recently Phase been SEFNELO, despite than
no disease multiple Slide Well, XX. a challenging The lupus to very on T cells, B multiple acts. is to date, of To signaling to across X reflect highly these an cells organ involve and attempts systems. everyone interconnected treat. turn predominantly most this and with acting It’s pathways, options acting me impacted molecule treat a simply X limited inflammatory reality interferon heterogeneous Please unfortunate
suppression Enlist, deplete for individual sale a signal. Senal while there’s generated And indicating diseases efficacy. suppresses somewhat B ultimately have long well. course, interferon history Both bitocytokine cells, modest but as of example, meaningful of attempts at cytokine inhibition,
together simultaneously. distinctively optimized both IL-XX. to IL-X AXX-axis The in activity or X IL-XX modulate pathogenic and and to Ceron migrates signal. and brepocitinib arm to TYKX address JUUL, selected axis IL-XX type and is B-cell TYKX all IL-XX T JAKX suppress Through the enforced maximum to IL-X, inhibition, JAKX are
Slide to turn XX. Please
of readouts including had evidence Phase and III JAKX, in inhibitor. data TYKX Phase data provide from inhibitor we’ve relevance months, JAKX illumin, a inhibitors clinical from each lupus, from therapeutic Phase JAK data the XX LINGO, from for II respectively. and II past the the Over of X JAK TYKX, data These inhibitor X Sotyktu
the water increased mid-teens mark particularly so as to time, effect. with none of benefit demonstrated roughly have same if such, far high molecules confidence in you the selling lupus In brepocitinib’s the some these Sotyktu At blooded and being placebo-adjusted. positive our across and
lupus. that none inflammatory actives unlike X and brepocitinib, expect, might these we molecules targets what of is all This given directly
and therapies oral greater from So efficacy we benefit and the are these cautiously physicians. inhibition for brepocitinib oral patients optimistic that become through and we’ve other deliver XX JAKX can than dual seen therapy leading
to Slide turn Please XX.
from We study ongoing expect this line fourth continue of our brepocitinib in lupus results the top of in to quarter year.
of As designed it we’ve the X the initiate endpoint would as primary confirmatory as we calls, XX a outcome, positive using In a we global earnings to X registrational this stated the large is to and previous of study expect cities. rapidly event such, in study. registrational second a is serve registrational
we’re can position as the deliver want in in optimistic confidence while the that do dermatomyositis. it is emphasize to I not will project data as here as that lupus, in success that cautiously brepocitinib our oral high leading therapy
had solid bet we, that feel Lupus matter, but the as regulatory a in that have in rock we in-licensed we pathways an out And efficacy underwrote refract. end as when that points core success hitting We that not we challenging such are just the was SRI and indication is proving industry, it mixed respect.
bed the fall these III potentially other Phase brepocitinib in enthusiasm in string other of had the about irrespective our lupus. to and is successful X large results our will orpediations in dermatomyositis indications remain we That studies the given rather in placebo-controlled opportunity date, of
Please Slide turn XX. to
now just to to have path dermatomyositis where a rapid DM. follow these we could launches with that Turning indications. I to X to closely potential want other market highlight in behind addition
A couple to guidance highlight here NIU or are NHS. noninfectious
no over year approved is DM, high targeted legal with year. therapy, in with a to Slide almost turn attributable specific to promotions. disease Unlike there is and despite of very dermatomyositis indication like per one sales approximately efficacy orphan XX,XXX limited blindness NIU, which large each has XX. generated burden $X.X Please billion a HUMIRA cases NIE indication
efficacious IU at biologic HUMIRA’s for potentially than in III or any The therapy indication development do this data, match is time DM open ongoing with oral compelling more and peak in significantly more. Phase wide with studies in this an could sales sufficiently could oral no competitive easily we landscape stages even
turn Slide XX. Please to
and we NIU. As have also clinical with validation of inhibition CM, JAKX
be U.S., it than may generated Before filgotinib JAKX development more by was in efficacious NIU data alpha suggesting discontinued suppression TNF has inhibition HUMIRA. II the Phase in
quite extent the validation in JAKX robustness NIU in However, as inhibition not clinical and is as of of DM. great
so moving to this rather a And Phase indication, are in than straight proof concept to. quick III, of we conducting
This efficient. dose pivotal that would ranging ensues more even make potential study a also study
that in XXXX. line expected this enrolled We’re the excited first study now to with is report of data top quarter fully
HS increased Slide prevalence disease DM Please awareness. highly and a debilitating turn and over time orphan through a to to XX. pattern a diagnosis with similar increasing NIU, large follows
approved and approximately promotion. therapy again, billion targeted stick limited limited indications sales with only the Here too, is $X indication-specific per HUMIRA year, to efficacy despite of
and turn therapies in X have development, JAKX XX. Slide inhibitors. oral HS does specifically Please DM other to Unlike later-stage NIU,
on that these from this than placebo-adjusted recently the either is and you by pace see of can generated As benefit slide, seen great molecules. brepocitinib
benefit observed and caused also Samira TNF II the growth study being XX% both despite and refractory discontinuation. robust. III patients heavily benefit in was surpasses by the placebo-adjusted and was TNF It generated impacted Phase Brepocitinib COVID-related XX% Phase program. Notably, benefit in brepocitinib naive its
inhibition, potentially to clinically supported actually which TYKX by placebo-adjusted benefit greater pathways, the HS the also suppressed demonstrate benefit II. fact, IL-XX an validated opportunity but XX inhibition. is in JAKX completers III In further Phase involves JAKX is This suggesting even not inflammatory among axis Phase but by only was mediated than XX%, not which pathobiology,
Please turn to Slide XX.
long patent mechanism hope action of up with I excited the franchise brepocitinib. convey potentially been in a specialty oral active that for autoimmune small leading molecule in industry. unique create to about are So us I’ve and life to a pharmaceutical we the the how able potential some sets part, It’s highly
a how and slide, this years. see you on pipeline will build in coming product this the Here
potential, HS XXXX. rapid follow orphan blockbuster be But without a for in this to both pivotal And launch pipeline indications and next in The of to other product business in a opportunity we in or have large successful then data DM program follow, $X coming proof-of-concept could later multibillion-dollar studies commercial large tees orphan lupus a with XXXX planned XXXX. year, potential other path And of even commercial XXXX. pivotal study with a in enrollment up rapid have in and our to with billion-plus potential there’s full derisk indications a readout lupus, alone. each launch initiated we NIU year clearly
personnel back compound I’d who participate generating all this trials to their to With that, patients for discovering that, turn and I’ll investigators, and And partnering in with all data in and thank importantly these their I’d like really the over of program, at to Zimmer as to it thank both for rest Matt. the Pfizer and so and this private of team all to with rich like far on colleagues set. on the work of our course, brepocitinib also well. the Ben course, for And site work us
